PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.72%
EBIT growth 5-10% – Moderate. Peter Lynch might look for ways the firm could optimize costs to boost EBIT further.
7.72%
Operating income growth 5-10% – Moderate. Peter Lynch would evaluate product-level profitability to see if certain segments could accelerate growth.
12.50%
Net income growth 10-15% – Solid. Seth Klarman would verify if cost control or pricing is driving consistent profit expansions.
15.94%
EPS growth 15-25% – Very strong. Benjamin Graham might verify if any one-time gains or tax benefits artificially inflate EPS.
15.94%
Diluted EPS growth 15-25% – Very strong. Benjamin Graham would verify that no large one-time items are skewing the diluted figure.
4.10%
Share count growth exceeding +3% – Notable dilution. Philip Fisher would want justification for new share issuance or acquisitions.
4.10%
Diluted share count growth above 3% – Noticeable dilution. Philip Fisher would question the rationale for issuing more stock or options.
No Data
No Data available this quarter, please select a different quarter.
-32.84%
Negative OCF growth is a critical warning sign. Benjamin Graham would check if receivables are ballooning or if core sales are declining.
-32.79%
Negative FCF growth reveals potential liquidity pressures or large capex overshadowing cash generation. Benjamin Graham would demand deeper scrutiny.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-48098.63%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
-29341.33%
A negative 5Y OCF/share CAGR indicates declining cash generation per share mid-term. Benjamin Graham would see this as a red flag unless explained by short-term strategic investments.
-23.11%
Negative 3Y OCF/share CAGR shows recent erosion in operating cash. Benjamin Graham would see this as a cautionary signal unless explained by strategic investments.
-39968.68%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
-32.05%
A negative 5Y net income/share CAGR reveals a mid-term deterioration in bottom-line earnings. Benjamin Graham would be cautious unless a credible turnaround is visible.
-188.96%
Negative 3Y net income/share CAGR highlights recent bottom-line decay. Benjamin Graham would want clarity on cost vs. revenue drivers for the declines.
7755.72%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
2687.68%
5Y equity/share CAGR above 12% – Strong mid-term book value expansion. Warren Buffett would see if steady profits and moderate payout ratios sustain this pace.
-9.18%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
Negative asset growth may reflect divestitures or depreciation outpacing new investments. Benjamin Graham wonders if shedding non-core assets improves focus or signals trouble.
-33.82%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
A big drop in R&D might boost near-term earnings but risk starving the pipeline. Benjamin Graham sees if the firm is refocusing or if future growth suffers.
-14.34%
Shrinking SG&A can raise profits short term, but might risk cutting key growth drivers. Benjamin Graham sees if this is sustainable.